Alanyl Glutamine
CAS 39537-23-0
Alanyl Glutamine (CAS 39537-23-0) is a Phase 3 pharmaceutical compound with 1 bioactivity target and 3 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 29782.608695652172 nM | 69 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| ALANYL GLUTAMINE | 1359422 | SU | MTHSPL |
| alanyl glutamine | 1359422 | SY | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Alanyl Glutamine used for in pharmaceutical contexts?
Alanyl Glutamine (CAS 39537-23-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Alanyl Glutamine?
Alanyl Glutamine has 3 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Anaphylactic shock, Hepatic function abnormal, Liver injury. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Alanyl Glutamine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for L-Alanyl-L-Glutamine with EU status "permitted".
What clinical phase is Alanyl Glutamine in?
Alanyl Glutamine is rendered with ChEMBL max phase 3.